Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
Taiho Pharmaceutical said on April 21 that another global PIII study on a combination therapy involving domvanalimab — an anti-TIGIT antibody that it has licensed in Japan from US biotech Arcus Biosciences — was discontinued after failing to show efficacy.…
To read the full story
Related Article
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Taiho Seals Trial Pact for Arcus Oncology Meds to Work with Gilead
May 19, 2023
- Taiho Exercises Option to Grab Arcus’ Anti-TIGIT Antibodies
December 1, 2021
BUSINESS
- Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
- Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
April 22, 2026
- Imdelltra Likely to Gain Ground in 2nd-Line SCLC after Label Update: Oncologist
April 22, 2026
- Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
- Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…